ÂÜŔňÂŇÂ×

Prof. Henning Walczak, Ph.D., completed his graduate and Ph.D. theses between 1990 and 1995 in Prof. Peter Krammer’s division at the German Cancer Research Center (DKFZ) in Heidelberg, Germany. In January 1996, he joined Immunex Corporation in Seattle, WA, USA. Following his return to Germany in 1998, he became a group leader in Prof. Krammer’s division at the DKFZ before he was awarded the BioFuture Prize in 1999 and subsequently appointed head of the BioFuture group Apoptosis Regulation’ at the DKFZ. In addition to his academic research activities, Prof. Walczak served as CEO/CSO for Apogenix Biotechnology AG, the predecessor of Apogenix GmbH, from 2000 to 2004. In 2007, he moved to the UK to become a Professor and Chair of Tumour Immunology at Imperial College London. In January 2013, he joined University College London as a Professor of Cancer Biology to take up his new role as Chair of the newly founded Centre for Cell Death, Cancer and Inflammation (CCCI) at the UCL Cancer Institute. Prof. Walczak is further Alexander von Humboldt Professor of Biochemistry at the medical faculty of the University of Cologne in Germany.